Patent: 9,657,310
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,657,310
Title: | Expression vector |
Abstract: | Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former. |
Inventor(s): | Takahashi; Kenichi (Hyogo, JP), Kakimoto; Shinji (Hyogo, JP) |
Assignee: | JCR PHARMACEUTICALS CO., LTD. (Ashiya-Shi, Hyogo, JP) |
Application Number: | 14/396,929 |
Patent Claims: | see list of patent claims |
Details for Patent 9,657,310
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biomarin Pharmaceutical Inc. | NAGLAZYME | galsulfase | Injection | 125117 | 05/31/2005 | See Plans and Pricing | 2032-04-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |